Sarcopenia is a progressive skeletal muscle disorder causing loss of muscle mass, strength, and function, contributing to frailty, falls, and disability in older adults. It remains underdiagnosed, delaying intervention. No approved pharmacological therapies exist; management focuses on exercise, nutrition, and underlying conditions. Ongoing research highlights novel targets, fueling drug development. DelveInsight's "Sarcopenia - Market Insight, Epidemiology, and Market Forecast - 2034" analyzes the disease in the US, EU4, UK, and Japan, covering clinical practices, unmet needs, and emerging therapies for primary and secondary sarcopenia. Despite pipeline potential, challenges include trial design and regulatory hurdles. Growing awareness, demographics, and diagnostic innovations promise steady progress. Request a sample and uncover the latest breakthroughs shaping the sarcopenia market landscape and future outlook @ [https://www.delveinsight.com/sample-request/sarcopenia-market?utm\_source=apac\&utm\_medium=promotion\&utm\_campaign=akpr](https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=apac\&utm_medium=promotion\&utm_campaign=akpr) Key highlights: * 7MM market size: USD 2.2 billion in 2024, growing to 2034. * U.S. share: USD 1.5 billion in 2025. * Prevalence: 18% in diabetics to 66% in esophageal cancer patients; 40% in liver cirrhosis. * 19.8 million diagnosed cases in 7MM in 2024. * U.S. 65-69 age group: \~4.52 million cases in 2024. * January 2025: IPS HEART's GIVI-MPCs received FDA ODD for BMD, with sarcopenia mouse model success. * January 2025: TNF Pharmaceuticals hit safety milestone for isomyosamine trials. * December 2024: FDA Fast Track for Lipocine Inc.'s LPCN 1148 in cirrhosis-related sarcopenia. * December 2024: TNF Pharmaceuticals' MYMD-1 Phase IIa data presented. * Emerging therapies: MYMD-1/Isomyosamine, LPCN 1148, BIO101, PF-1801, RJx-01, KER-065, BPM 31510, OC514, MT29, TRN-005, NMDP-05, PF1807, DW1030, etc. * Key companies: MyMD Pharmaceuticals, Biophytis, Dystrogen Therapeutics, Rejuvenate Biomed, Oncocross Therapeutics, OPKO Health, NMD Pharma, Rubedo Life Sciences, Immunoforge, etc. Curious to see the graphical version of these numbers? The sarcopenia infographic is ready for you, check it out here: [https://www.delveinsight.com/infographics/sarcopenia-market?utm\_source=apac\&utm\_medium=promotion\&utm\_campaign=akpr](https://www.delveinsight.com/infographics/sarcopenia-market?utm_source=apac\&utm_medium=promotion\&utm_campaign=akpr) ### **Sarcopenia Overview** Sarcopenia involves age-related muscle loss, increasing fall, disability, and mortality risks. It can stem from chronic diseases. Diagnosis assesses strength, mass, and performance. Drug options are limited; focus is on exercise and nutrition. Molecular insights drive new therapies. Get a free sample for the sarcopenia market forecast, size & share analysis report: [https://www.delveinsight.com/sample-request/sarcopenia-market?utm\_source=apac\&utm\_medium=promotion\&utm\_campaign=akpr](https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=apac\&utm_medium=promotion\&utm_campaign=akpr) ### **Sarcopenia Epidemiology** Covers trends in 7MM (2020-2034), segmented by total, gender, age, and severity of diagnosed prevalent cases. ### **Sarcopenia Drugs Uptake and Pipeline Development Activities** Analyzes adoption of new therapies, uptake rates, and pipeline profiles, including partnerships and strategic moves. At present, there are very limited clinical trials in sarcopenia sponsored or co‑sponsored by companies based exclusively in Japan, Korea, or Taiwan that meet the criteria of Phase 1–3 drug intervention activity. The majority of interventional therapeutic development to date has been conducted by global pharmaceutical companies or has focused on observational, lifestyle, nutrition, or biomarker studies rather than company‑sponsored drug development. Below is a comprehensive list of all known relevant clinical investigations with Japanese, Korean, or Taiwanese organizational involvement — including registry IDs where available — plus the most up‑to‑date data on mechanisms and development status. (Where company sponsors are not primarily pharmaceutical/drug developers, this is noted.) Company Name & Country: ヒューマンライフコード株式会社 — Japan Drug Candidate / Intervention: UC‑MSC cells (umbilical cord‑derived mesenchymal stem cells) Trial Phase: Exploratory clinical study (not a formal Phase 1–3 therapeutic drug trial) Mechanism of Action (MOA): Cell therapy with MSCs to explore biologic biomarkers and potential impact on sarcopenia pathophysiology, focusing on regenerative and immune‑modulatory effects Clinical Activity / Trial Info: Ongoing sarcopenia biomarker clinical research in Brazil with completion of participant enrollment and blood biomarker collections, expected data analysis in 2025; this early clinical study supports future therapeutic development. Latest Development: Trial subject enrollment of 70 participants completed; data analysis expected to guide further therapy strategies. Registry ID: Not available (reported via corporate press release). Note: While there are Korean companies engaged in muscle‑related biomedical technology (e.g., Biobytes), no interventional Phase 1–3 drug trials for therapeutic sarcopenia drugs sponsored by Korean pharmaceutical companies currently appear in major registries as of the latest available data. One South Korean biotech startup (Biobytes) is developing health tools and diagnostics around sarcopenia risk and related gene signals, but there is no separate Phase 1–3 drug trial entry in clinical registries yet. Regional Multinational Trial Participation (Non‑Regional Sponsors) While not sponsored by Japanese/Korean/Taiwanese companies themselves, there have been global sarcopenia drug programs that included sites in Asia (including Japan and Korea). These do not meet the sponsor requirement but are relevant for context: Novartis / International Study of Bimagrumab Sponsor: Novartis (global pharmaceutical company) Drug Candidate: Bimagrumab (monoclonal antibody targeting myostatin/activin type II receptor to induce muscle hypertrophy) Phase: Phase II (some trials included Japanese and Korean sites) MOA: Myostatin/ActRII blockade to promote skeletal muscle growth Clinical Trial Registry: NCT02333331 Latest Development: Phase II dose‑finding study showed increases in lean body mass but no meaningful functional improvement over placebo in primary outcomes; research continues to inform future candidate design. Registry ID: NCT02333331. Summary of Active Clinical Development in Sarcopenia by Region Japan: Human Life CORD (MSC therapy exploratory research), Tokyo University (Neurotropin® in sarcopenia pain context), UMIN combination treatment research — no approved or advancing Phase 1–3 drug candidates yet outside observational or academic interventions. Taiwan: Asia University nutritional intervention trial — not a pharmaceutical drug but relevant physiologic study. Korea: No Phase 1–3 therapeutic drug development trials listed in major registries by Korean sponsors as of now; startup activity focuses more on diagnostic/health tool innovations. Sources Because sarcopenia therapeutic drug development is still emerging in East Asia, there are limited company‑sponsored Phase 1–3 pharmacologic drug trials in Japan, Korea, or Taiwan specifically registered. The above reflects all available clinical registry entries and reported corporate trials relevant to sarcopenia from these regions as of 2026. Explore how emerging sarcopenia therapies are aligning with evolving patient populations @ [https://www.delveinsight.com/sample-request/sarcopenia-market?utm\_source=apac\&utm\_medium=promotion\&utm\_campaign=akpr](https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=apac\&utm_medium=promotion\&utm_campaign=akpr) ### **Sarcopenia Market Outlook** Untapped market with no approved drugs; relies on lifestyle changes. Pipeline candidates like MYMD-1, LPCN 1148, and BIO101 offer hope. Targeted therapies and early diagnosis will drive growth to 2034. ### **Sarcopenia Market Drivers** * Aging population increases demand for diagnostics and treatments. * Better awareness and diagnostic tools enable earlier intervention. ### **Sarcopenia Market Barriers** * No FDA/EMA-approved drugs hinder innovation. * Underrecognition as normal aging limits diagnosis. ### **Scope of the Sarcopenia Market Report** * Study Period: 2020-2034 * Coverage: 7MM (US, EU5, Japan). * Key Companies: MyMD Pharmaceuticals, Biophytis, Dystrogen Therapeutics, Rejuvenate Biomed, Oncocross Therapeutics, OPKO Health, NMD Pharma, Rubedo Life Sciences, Immunoforge, etc. * Key Therapies: MYMD-1/Isomyosamine, LPCN 1148, BIO101, PF-1801, RJx-01, KER-065, BPM 31510, OC514, MT29, TRN-005, NMDP-05, PF1807, DW1030, etc. * Therapeutic Assessment: Marketed and emerging therapies. * Market Dynamics: Drivers and barriers. * Competitive Intelligence: SWOT, PESTLE, Porter's five forces, BCG Matrix, entry strategies. * Unmet Needs, KOL/Analyst views, Market Access and Reimbursement. **About DelveInsight** DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. **Related report** [**Sarcopenia Epidemiology Forecast - 2034**](https://www.delveinsight.com/report-store/sarcopenia-epidemiology-forecast?utm_source=apac\&utm_medium=promotion\&utm_campaign=akpr) DelveInsight’s ‘Sarcopenia - Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the sarcopenia, historical and forecasted epidemiology trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The leading Sarcopenia Companies developing potential therapies include - TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, and others. [**Sarcopenia Pipeline Insight, 2025**](https://www.delveinsight.com/report-store/sarcopenia-pipeline-insight?utm_source=apac\&utm_medium=promotion\&utm_campaign=akpr) DelveInsight’s, “Sarcopenia - Pipeline Insight, 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Sarcopenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. The leading Sarcopenia Companies developing potential therapies include - TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, and others. #### Media Contact **Company Name:** [DelveInsight Business Research LLP](https://www.delveinsight.com/consulting) **Contact Person:** Abhishek kumar **Email:** [abhishek@delveinsight.com](mailto:abhishek@delveinsight.com) **City:** Albany **State:** New York **Country:** United States **Website**:[ https://www.delveinsight.com](https://www.delveinsight.com/)

Articles

Why Businesses in India Are Choosing X Advertising Services

Latest Articles

Best Place To Buy Old Twitter Accounts In (Bestusamarket)

Sarcopenia Market Set for Strong Growth by 2034

Accelerate Past Your Ticket with Motoring Defence: Your Speeding Offence Lawyers